Galectin Therapeutics (GALT) Liabilities and Shareholders Equity (2010 - 2026)

Galectin Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $15.8 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 65.4% year-over-year to $15.8 million in Q1 2026; TTM through Mar 2026 was $63.8 million, a 23.78% decrease from a year earlier, with the FY2025 full-year figure at $19.5 million, up 11.64% from the prior year.
• Liabilities and Shareholders Equity declined to $15.8 million in Q1 2026 per GALT's latest filing, from $19.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $33.6 million in Q1 2022 and bottomed at $9.5 million in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $20.2 million (2023), against an average of $21.3 million.
• Across the five-year window, Liabilities and Shareholders Equity slumped 63.2% in 2025 and soared 65.4% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $21.3 million in 2022, then jumped by 32.49% to $28.2 million in 2023, then sank by 37.96% to $17.5 million in 2024, then rose by 11.64% to $19.5 million in 2025, then declined by 19.32% to $15.8 million in 2026.
• Per Business Quant, the three latest GALT Liabilities and Shareholders Equity figures stand at $15.8 million (Q1 2026), $19.5 million (Q4 2025), and $12.9 million (Q3 2025).